CEO Barry Richard Buys $78K of Filana Stock at $0.84
FLNA sits 45% above its 52-week low of $0.67 on light trading volume (0.4× avg).
Summary
CEO Barry Richard bought $78,196 of Filana stock at $0.84 per share on September 28, 2026, held via trust.
Key Events · Ownership and Investor Activity · FLNA
-
CEO Open-Market Purchase
Barry Richard, President & CEO, bought 93,091 shares at a weighted average of $0.84 per share (range $0.82-$0.85) on September 28, 2026, totaling $78,196.44.
-
Purchase Held Via Trust
The shares are held indirectly by a trust; post-transaction holdings total 1,031,151 shares.
-
Context: Delisting Notice and FDA Hold Lift
The purchase follows a September 17, 2026 Nasdaq notice for trading below $1.00 for 30 consecutive days, and the September 22, 2026 FDA lift of the clinical hold on simufilam.
Analysis · FLNA · Life Sciences
President & CEO Barry Richard purchased 93,091 shares on the open market at a weighted average of $0.84 per share, spending $78,196.44. The buy comes just days after the FDA lifted the clinical hold on simufilam and while the stock trades below $1.00, facing a Nasdaq delisting notice. A CEO putting real cash into the stock at this juncture is a meaningful vote of confidence in the company's ability to regain compliance and advance its pipeline.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29% of the 1517 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FLNA was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.8M. The 52-week trading range was $0.67 to $4.98. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.